A drug related to the class of proton pump inhibitors, most effective in reducing gastric acid secretion, was approved for the use in children.

On May 29, 2007 AstraZeneca, the maker of Prilosec (omeprazole) and Nexium (esomeprazole), sent FDA data from two long-term studies in patients with severe gastroesophageal reflux disease (GERD) that were being treated with either Prilosec or Nexium.